Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 497-504

  Scagliotti, Giorgio V ^a   Bondarenko, I ^b   Blackhall, F ^c   Barlesi, F ^d   Hsia, T C ^e   Jassem, J ^f   Milanowski, J ^g   Popat, S ^h   Sanchez Torres, J M ⁱ   Novello, S ^a   Benner, R J ^j   Green, S ^j   Molpus, K ^j   Soria, J C ^k   Shepherd, F A ^l  

^a UNIVERSITY OF TURIN   (Italy)

^b Dnipropetrovsk State Medical Academy   (Ukraine)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d AIX MARSEILLE UNIVERSITY   (France)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j PFIZER INC   (United States)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Erlotinib; Figitumumab; Nonsmall cell lung cancer

Indexed keywords

ANTIDIABETIC AGENT; ERLOTINIB; FIGITUMUMAB; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ALLERGIC PNEUMONITIS; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; BACKACHE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG RECALL; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARREST; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; INTESTINE ISCHEMIA; KIDNEY FAILURE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SIDE EFFECT; SURVIVAL TIME; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84930946251     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu517     Document Type: Article

References (19)

1. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-289.
2. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619.
3. Nicholson RI, Hutcheson IR, Knowlden JM et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10(1 Pt 2): 346S-354S.
4. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005; 7: R570-R579.
5. Steinbach JP, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem Biophys Res Commun 2004; 321: 524-530.
6. Goetsch L, Gonzalez A, Leger O et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113: 316-328.
7. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-10111.
8. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the antiinsulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
9. Lacy MQ, Alsina M, Fonseca R et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
10. Karp DD, Paz-Ares LG, Novello S et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27: 2516-2522.
11. Karp DD, Paz-Ares LG, Novello S et al. Retraction. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2012; 30: 4179.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Olmos D, Postel-Vinay S, Molife LR et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11: 129-135.
14. Ramalingam SS, Spigel DR, Chen D et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011; 29: 4574-4580.
15. Johnson JR, Cohen M, Sridhara R et al. Approval summary of erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11: 6414-6421.
16. Atzori F, Tabernero J, Cervantes A et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6304-6312.
17. Naing A, Kurzrock R, Burger A et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011; 17: 6052-6060.
18. Langer CJ, Novello S, Park K et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small cell lung cancer. J Clin Oncol 2014; 32: 2059-66.
19. Gualberto A, Hixon ML, Karp DD et al. Retraction. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2012; 107: 2024.